Form 4 for ACAD ACADIA PHARMACEUTICALS INC

Accepted 2024-08-20 00:00:00 ET · period of report 2024-08-16 · accession 0001415889-24-021726 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2024-08-20	2024-08-19	ACAD	Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	S - Sale	$15.28	-9,534	52.2K	-15%	-$145.7K
M	2024-08-20	2024-08-16	ACAD	Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	A - Grant	$0.00	+18.7K	61.7K	+43%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-08-19	S	D	9,534	$15.28	52,177	D	—	—	(F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
2	Common	Common Stock	2024-08-16	A	A	5,024	$0.00	48,082	D	—	—	(F1) Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target. (F2) Includes 925 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.
3	Common	Common Stock	2024-08-16	A	A	13,629	$0.00	61,711	D	—	—	(F3) Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.